Derik De Bruin
Stock Analyst at B of A Securities
(3.59)
# 691
Out of 5,182 analysts
205
Total ratings
64.79%
Success rate
13.74%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $410 → $350 | $320.00 | +9.38% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $37.59 | +59.62% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $115.06 | +43.40% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,325.01 | +4.90% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $189.61 | +16.03% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $57.89 | -53.36% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $89.79 | +22.51% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $23.27 | -44.13% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $40.89 | +23.45% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.35 | +152.87% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $7.69 | +108.06% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $496.11 | +33.04% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $167.34 | +40.43% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $175.65 | +19.56% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $256.55 | +38.37% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $13.52 | +92.31% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $260.93 | +3.86% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $191.51 | -4.97% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $9.17 | +129.01% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $11.37 | +181.44% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $120.93 | -17.31% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $2.63 | +394.30% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.68 | +286.90% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $106.81 | +143.42% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $6.45 | +1,760.47% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $117.86 | +1.82% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.92 | +368.75% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $563.00 | -58.26% | 3 | Nov 2, 2018 |
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $320.00
Upside: +9.38%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $37.59
Upside: +59.62%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $115.06
Upside: +43.40%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,325.01
Upside: +4.90%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $189.61
Upside: +16.03%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $57.89
Upside: -53.36%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $89.79
Upside: +22.51%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $23.27
Upside: -44.13%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $40.89
Upside: +23.45%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.35
Upside: +152.87%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.69
Upside: +108.06%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $496.11
Upside: +33.04%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $167.34
Upside: +40.43%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $175.65
Upside: +19.56%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $256.55
Upside: +38.37%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $13.52
Upside: +92.31%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $260.93
Upside: +3.86%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $191.51
Upside: -4.97%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $9.17
Upside: +129.01%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $11.37
Upside: +181.44%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $120.93
Upside: -17.31%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $2.63
Upside: +394.30%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.68
Upside: +286.90%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $106.81
Upside: +143.42%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $6.45
Upside: +1,760.47%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $117.86
Upside: +1.82%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.92
Upside: +368.75%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $563.00
Upside: -58.26%